---
document_datetime: 2025-04-23 16:00:41
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/kinzalmono-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: kinzalmono-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.1622528
conversion_datetime: 2025-12-28 18:23:12.206951
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Kinzalmono

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, please also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                            |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------|
| Variation type IB /  | This was an application for a group of | 03/04/2025                          |                                             | SmPC, Annex                      | To change the description \"angiotensin II receptor |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000242970   | variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Other variation - Accepted To change the description \"angiotensin II receptor antagonists\" to \"angiotensin II receptor blockers\" throughout the annexes. In addition the MAH has corrected the Sorbitol quantity in the 80 mg tablets and brought the annexes in line with the current QRD version and updated the local representative in Norway.   | II and PL   | antagonists\" to \"angiotensin II receptor blockers\" throughout the annexes. In addition the MAH has corrected the Sorbitol quantity in the 80 mg tablets and brought the annexes in line with the current QRD version and updated the local representative in Norway.   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|